A
Anne Cross
Researcher at Bristol-Myers Squibb
Publications - 40
Citations - 5326
Anne Cross is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Didanosine & Entecavir. The author has an hindex of 24, co-authored 40 publications receiving 5219 citations.
Papers
More filters
Journal ArticleDOI
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B
Ting-Tsung Chang,Robert G. Gish,Robert A. de Man,Adrián Gadano,Jose D. Sollano,You Chen Chao,Anna S. Lok,Kwang Hyub Han,Zachary Goodman,J. Zhu,Anne Cross,Deborah DeHertogh,R B Wilber,Richard J. Colonno,David Apelian +14 more
TL;DR: Among patients with HBeAg-positive chronic hepatitis B, the rates of histologic, virologic, and biochemical improvement are significantly higher with entecavir than with lamivudine, and the safety profile of the two agents is similar.
Journal ArticleDOI
Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B
Ching-Lung Lai,Daniel Shouval,Anna S. Lok,Ting-Tsung Chang,Hugo Cheinquer,Zachary Goodman,Deborah DeHertogh,R B Wilber,Richard C. Zink,Anne Cross,Richard J. Colonno,Lori Fernandes +11 more
TL;DR: Among patients with HBeAg-negative chronic hepatitis B who had not previously been treated with a nucleoside analogue, the rates of histologic improvement, virologic response, and normalization of alanine aminotransferase levels were significantly higher at 48 weeks with entecavir than with lamivudine.
Journal ArticleDOI
Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B.
Morris Sherman,Cihan Yurdaydin,Jose D. Sollano,Marcelo Silva,Yun Fan Liaw,Janusz Cianciara,Anna Boron–Kaczmarska,Paul Martin,Zachary Goodman,Richard J. Colonno,Anne Cross,Gail Denisky,Bruce Kreter,R. Hindes +13 more
TL;DR: In patients with lamivudine-refractory chronic hepatitis B, switching to entecavir provides superior histologic improvement, viral load reduction, and ALT normalization compared with continuing lamivUDine, with a comparable adverse event profile.
Journal ArticleDOI
Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study.
Michael S. Simberkoff,Anne Cross,Mohamed S. Al-Ibrahim,A. L. Baltch,P J Geiseler,J Nadler,A S Richmond,R. P. Smith,Gerald Schiffman,D S Shepard +9 more
TL;DR: The data suggest that chronically ill patients, who are most susceptible to infection, may have an impaired immune response to the pneumococcal vaccine.
Journal ArticleDOI
A Controlled Trial Comparing Continued Zidovudine with Didanosine in Human Immunodeficiency Virus Infection
James O. Kahn,Stephen W. Lagakos,D. D. Richman,Anne Cross,Carla Pettinelli,Liou Sh,Brown M,Paul A. Volberding,Clyde S. Crumpacker,Gildon N. Beall +9 more
TL;DR: Changing treatment from zidovudine to 500 mg per day of didanosine appears to slow the progression of HIV disease.